# XYNGARI (DMT310) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/dmt310

> XYNGARI (DMT310), sponsored by Dermata Therapeutics, Inc. (DRMA): 4 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | XYNGARI (DMT310) |
| Codes | DMT310 |
| Sponsor | Dermata Therapeutics, Inc. (DRMA) https://sec-api.dev/companies/drma/catalysts |
| Indications | moderate-to-severe acne |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jun 2023: trial start

- Status: completed. Date confidence: month. Stage: 2.
- First seen 2025-03-17, last confirmed 2025-03-17.
- SEC Form 10-K (accession 0001654954-25-002885): "After receiving positive feedback and alignment with FDA from our End of Phase 2 meeting in June of 2023 we began enrolling patients in our XYNGARI™ Phase 3 STAR-1 clinical trial in moderate-to-severe acne in December 2023." https://www.sec.gov/Archives/edgar/data/1853816/000165495425002885/drma_10k.htm

### March 27, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3.
- First seen 2024-11-13, last confirmed 2025-11-14.
- Press release filed with the SEC (EX-99) (accession 0001654954-25-003372): "SAN DIEGO, CA, March 27, 2025 - Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced positive topline results from the Company's first pivotal Phase 3 trial of XYNGARI™, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne." https://www.sec.gov/Archives/edgar/data/1853816/000165495425003372/drma_ex991.htm
- SEC Form 10-Q (accession 0001493152-25-023474): "March 2025, the Company announced positive topline results for its XYNGARI™ Phase 3 STAR-1 clinical trial." https://www.sec.gov/Archives/edgar/data/1853816/000149315225023474/form10-q.htm
- SEC Form 10-Q (accession 0001641172-25-023572): "March 2025, the Company announced positive topline results for its XYNGARI™ Phase 3 STAR-1 clinical trial." https://www.sec.gov/Archives/edgar/data/1853816/000164117225023572/form10-q.htm
- Press release filed with the SEC (EX-99) (accession 0001654954-25-002886): "- Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial by end of March 2025 -" https://www.sec.gov/Archives/edgar/data/1853816/000165495425002886/drma_ex991.htm
- Press release filed with the SEC (EX-99) (accession 0001654954-25-002886): "Dermata plans to announce topline results from the XYNGARI™ Phase 3 STAR-1 trial by the end of March 2025." https://www.sec.gov/Archives/edgar/data/1853816/000165495425002886/drma_ex991.htm
- Press release filed with the SEC (EX-99) (accession 0001654954-24-014289): ""The third quarter was a busy time for our team as we approach completing enrollment in our DMT310 Phase 3 STAR-1 study and were able to raise funds, which we believe will allow us to reach the topline data readout in the STAR-1 study in the first quarter of 2025," commented Gerry Proehl, Dermata's Chairman, President, and Chief Executive Officer." https://www.sec.gov/Archives/edgar/data/1853816/000165495424014289/drma_ex991.htm
- Press release filed with the SEC (EX-99) (accession 0001654954-24-014289): "Dermata expects to complete enrollment in the STAR-1 study by the end of 2024 and plans to announce topline results from the DMT310 Phase 3 STAR-1 study in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1853816/000165495424014289/drma_ex991.htm
- SEC Form 10-K (accession 0001654954-25-002885): "The STAR-1 Phase 3 study is expected to have top-line results in the March of 2025.Previously, we completed a randomized, double-blind, multicenter, placebo-controlled Phase 2b clinical trial of XYNGARI™ for the once weekly treatment of moderate-to-severe acne." https://www.sec.gov/Archives/edgar/data/1853816/000165495425002885/drma_10k.htm
- SEC Form 10-Q (accession 0001654954-24-014274): "We recently announced enrollment of 50% of the total expected patients in the STAR-1 study and we expect to have top-line results from the first Phase 3 study in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1853816/000165495424014274/drma_10q.htm
- SEC Form 10-Q (accession 0001654954-24-014274): "We expect to receive top-line results from the first Phase 3 trial, referred to as STAR-1, in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1853816/000165495424014274/drma_10q.htm

### April 15, 2025: topline data readout

- Status: completed, met. Date confidence: exact.
- First seen 2024-11-14, last confirmed 2025-04-15.
- Press release filed with the SEC (EX-99) (accession 0001654954-25-004265): "SAN DIEGO, CA, April 15, 2025 - Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications, today announced that additional analysis of topline data from its Phase 3 STAR-1 trial showed that XYNGARI™ had a statistically significant difference from placebo on three efficacy endpoints as early as week 4, which occurred after just four treatments with XYNGARI™." https://www.sec.gov/Archives/edgar/data/1853816/000165495425004265/drma_ex991.htm
- Press release filed with the SEC (EX-99) (accession 0001654954-24-014289): "After achieving the 50% enrollment milestone in July 2024, Dermata expects to receive topline results from the STAR-1 study in the first quarter of 2025." https://www.sec.gov/Archives/edgar/data/1853816/000165495424014289/drma_ex991.htm

### late 2025: trial start

- Status: scheduled. Date confidence: half. Stage: 3. Indication: moderate-to-severe acne.
- First seen 2025-05-14, last confirmed 2025-05-14.
- Press release filed with the SEC (EX-99) (accession 0001641172-25-010112): "With positive results from the STAR-1 trial, Dermata has begun the manufacturing campaign for the STAR-2 trial and plans to initiate the second Phase 3 trial of XYNGARI™ for the treatment of moderate-to-severe acne by the end of 2025." https://www.sec.gov/Archives/edgar/data/1853816/000164117225010112/ex99-1.htm
- SEC Form 10-Q (accession 0001641172-25-010111): "Based on this positive data, we plan initiate the second XYNGARI™ Phase 3 STAR-2 trial by the end of 2025." https://www.sec.gov/Archives/edgar/data/1853816/000164117225010111/form10-q.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/dmt310.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "XYNGARI (DMT310) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/dmt310

```bibtex
@misc{secapidev_pdufa_dmt310_20261116,
  title        = {XYNGARI (DMT310) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/dmt310}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_dmt310_20261116","title":"XYNGARI (DMT310) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/dmt310","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
